Published online Jul 6, 2022. doi: 10.12998/wjcc.v10.i19.6529
Peer-review started: October 6, 2021
First decision: December 4, 2021
Revised: December 19, 2021
Accepted: May 8, 2022
Article in press: May 8, 2022
Published online: July 6, 2022
Processing time: 261 Days and 1.1 Hours
Triple A syndrome is a rare autosomal recessive disease characterized by adrenocorticotropic hormone-resistant adrenal insufficiency, alacrima and achalasia. In the last 5 years, per-oral endoscopic myotomy (POEM) has proved highly successful in treating primary achalasia over the long term, but its long-term performance has not been certified by achalasia related to Triple A syndrome.
Triple A syndrome is a rare autosomal recessive disease characterized by adrenocorticotropic hormone-resistant adrenal insufficiency, alacrima and achalasia. In the past 5 years, POEM has proved highly successful in treating primary achalasia over the long term, but its long-term performance has not been certified by achalasia related to Triple A syndrome. Eckardt scores and esophageal manometry improved significantly during the 2 years following POEM; however, grade-A reflux esophagitis recurred in 66.7% of patients in 12 mo post-procedure.
Based on these case studies, POEM is efficacious and safe for a treatment of achalasia associated with Triple A syndrome.
Core Tip: Per-oral endoscopic myotomy (POEM) has proved an ideal way to treat primary achalasia in both short- and long-term but there is little evidence for achalasia related to Triple A syndrome, a rare disease. Herein, we enrolled three patients and performed POEM on them. During the following 2 years, we evaluated them by Eckardt score, barium swallowing test and Esophagogastroduodenoscopy. As a result, they all improved in all aspects.